A systematic review of the use of economic evaluation in local decision-making

Health Policy

Volumn 86, Issue 2-3, 2008, Pages 129-141

  Eddama, Oya ^a   Coast, Joanna ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Decision making; Economic evaluation; Evidence

Indexed keywords

CULTURAL FACTOR; DECISION MAKING; ECONOMIC EVALUATION; EMPIRICAL RESEARCH; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH CENTER; HEALTH SURVEY; HUMAN; POLITICS; REVIEW; SYSTEMATIC REVIEW;

DECISION MAKING; HEALTH CARE RATIONING; LOCAL GOVERNMENT; MODELS, ECONOMETRIC;

EID: 40849147260     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2007.11.010     Document Type: Review

References (76)

1. Drummond M., O'Brien B., Stoddart G., and Torrance G. Methods for the economic evaluation of health care programmes (1997), Oxford University Press: Oxford Medical Publications
2. Economic, and Evaluation. In: Fox-Rushby J., and Cairns J. (Eds). Understanding public health series (2005), Open University Press
3. Duckett S.J. Drug policy down under: Australia's pharmaceutical benefits scheme. Health Care Finance Review 25 3 (2004) 55-67
4. Ontario Ministry of Health. Ontario Guidelines for Economic Evaluation of Pharmaceutical Products. Ministry of Health and Long Term Care. 1994.
5. National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal (2004), NICE, London
6. Bryan S., Williams I., and McIver S. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. Health Economics 16 2 (2007) 179-193
7. Van Velden M.E., Severens J.L., and Annoesjka N. Economic evaluations of healthcare programmes and decision making. The influence of economic evaluations on different healthcare decision-making levels. Pharmacoeconomics 23 11 (2005) 1075-1082
8. Ham C. Health policy in Britain (2004), Palgrave Macmillan
9. Le Grand J. The labour government and the National Health Service. Oxford Review of Economic Policy 18 (2002) 137-153
10. Graf von der Schulenburg J.M. The influence of economic evaluation studies on health care decision making. A European survey. (2000), IOS Press and Ohmsha, Amsterdam
11. Alban A. Economic appraisal: what is the use? third nordic health economists' study group meeting. Finland (1982)
12. Alban A. Economic appraisal: what is the use? revisited. Eight nordic health economists' study group meeting. Finland (1987)
13. Ludbrook A. Economic appraisal in the National Health Service: a survey. Health Policy 6 (1986) 21-31
14. Davies L., Coyle D., and Drummond M. Current status of economic appraisal of health technology in the European Community: report of the network. Social Science & Medicine 38 (1994) 1601-1607
15. McNamee P., and Godber E. Assessing and applying effectiveness and cost effectiveness evidence in purchasing organisations: problems and prospects. Health Economists' Study Group. Aberdeen (1995)
16. Ross J. The use of economic evaluation in health care: Australian decision makers' perceptions. Health Policy 31 (1995) 103-110
17. Luce B.R., and Brown R.E. The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the Unites States. International Journal of Technology Assessment in Health Care 11 (1995) 79-92
18. Steiner C., Powe N., and Anderson G. Coverage decisions for medical technology by managed care: relationship to organizational and physician payment characteristics. American Journal of Managed Care 2 (1996) 1321-1331
19. Steiner C., Powe N., Anderson G., and Das A. The review process used by U.S. health care plans to evaluate new medical technology and coverage. Journal of General Internal Medicine 11 (1996) 294-302
20. Walley T., Barton S., Cooke J., and Drummond M. Economic evaluations of drug therapy: attitudes of primary care prescribing advisers in Great Britain. Health Policy 41 (1997) 61-72
21. Sloan F.A., Whetten-Goldstein K., and Wilson A. Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis. Social Science & Medicine 45 (1997) 523-533
22. Lyles A., Luce B.R., and Rentz A.M. Managed care pharmacy, socioeconomic assessments and drug adoption decisions. Social Science & Medicine 45 (1997) 511-521
23. Drummond M., Cooke J., and Walley T. Economic evaluation under managed competition: evidence from the UK. Social Science & Medicine 45 (1997) 583-595
24. Duthie T., Trueman P., Chancellor J., and Diez L. Research into the use of health economics in decision making in the United Kingdom. Phase II. Is health economics 'for good or evil'?. Health Policy 46 (1999) 143-157
25. Evans C., Dukes E., and Crawford B. The Role of pharmacoeconomic information in the formulary decision-making process. Journal of Managed Care in Pharmacy 6 (2000) 108-121
26. Cox E., Motheral B., and Griffis D. Relevance of pharmacoeconomics and health outcomes information to health care decision makers in the United States. Value Health 3 (2000) 162
27. Grizzle A., Motheral B., Garrity B., Cox E., and Armstrong E. A qualitative assessment of managed care decision maker's views and use of pharmacoeconomic information. Value Health 3 (2000) 162-163
28. Motheral B., Grizzle A., Armstrong E., Cox E., Bataoel J., Bennett D., et al. A national survey of decision-makers in managed care organisations on their views and use of pharmacoeconomic information. Value Health 3 (2000) 162-163
29. Anell A., and Svarvar P. Pharmacoeconomics and clinical practice guidelines. A survey of attitudes in Swedish formulary committees. Pharmacoeconomics 17 (2000) 175-185
30. Ginsberg M.E., Kravitz R., and Sandberg W. A survey of physician attitudes and practices concerning cost-effectiveness in patient care. Western Journal of Medicine 173 (2000) 390-394
31. Rosen R. Applying research to health care policy and practice: medical and managerial views on effectiveness and the role of research. Journal of Health Services Research and Policy 5 (2000) 103-108
32. Hoffmann C., and von der Schulenburg J.M.G. The influence of economic evaluation studies on decision making. A European survey. The EUROMET group. Health Policy 52 (2000) 179-192
33. Burns A. Better information, better outcomes? The use of health technology assessment and clinical effectiveness data in health care purchasing decisions in the United Kingdom and United States. Milbank Memorial Fund Quarterly (2000) 1-26
34. Kulsomboon V., Palumbo F., and Mullins C. Criteria to request pharmacoeconomic data and data sources for hospital formulary decisions. Drug Information Journal 35 (2001) 231-240
35. McDonald R., and Baughan S. Rationality and reality: attitudes of health economists working at local level in the UK National Health Service. Critical Public Health 11 (2001) 319-330
36. Folakemi T., Sullivan J., Nash R., and Clemmons C. Use of pharmacoeconomic data in making hospital formulary decisions. American Journal of Health-System Pharmacists 59 (2002) 1441-1444
37. West R., Borden E., Collet J.-P., Rawson N., and Tonks R. Cost-effectiveness estimates result in flawed decision-making in listing drugs for reimbursement. Canadian Journal of Public Health 93 (2002) 421-425
38. Weatherly H., Drummond M., and Smith D. Use of economic evidence in the design of Health Improvement Programmes (HImPS) (2002), Centre for Health Economics, York
39. Nixon J., Phipps K., Glanville J., Mugford M., and Drummond M. Using economic evidence to support decision making: a case study of assertive community treatment within the UK National Service Framework for Mental Health. Applied Health Economics & Health Policy 1 (2002) 179-190
40. McDonald R. Using health economic in health services. Rationing rationally? (2002), Open University Press
41. Johnstone P., and Lacey P. Are decisions by purchasers in an English health district evidence-based?. Journal of Health Services Research & Policy 7 (2002) 166-169
42. Hoffmann C., Stoykova B.A., Nixon J., Glanville J.M., Misso K., and Drummond M.F. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value in Health 5 (2002) 71-78
43. Drummond M, Brown R, Fendrick AM, Fullerton P, Neumann P, Taylor R, Barbieri M. Use of pharmacoeconomics information. Report of the ISPOR task force on use of pharmacoeconomic/health economic information in health-care decision making. Value in Health 2003; 6:407-416.
44. Ubel P.A., Jepson C., Baron J., Hershey J.C., and Asch D.A. The influence of cost-effectiveness information on physicians' cancer screening recommendations. Social Science & Medicine 56 (2003) 1727-1736
45. IJzerman M., Reuzel R., and Severens H. Pre-assessment to assess the match between cost-effectiveness results and decision makers' information needs. International Journal of Technology Assessment in Health Care 19 (2003) 17-27
46. Sheldon T.A., Cullum N., Dawson D., Lankshear A., Lowson K., Watt I., et al. What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews. British Medical Journal 329 (2004) 1-8
47. Wu O., Knill-Jones R., Wilson P., and Craig N. The impact of economic information on medical decision making in primary care. Journal of Evaluation in Clinical Practice 10 3 (2004) 407-411
48. Haslé-Pham E., Arnould B., Späth H.-M., Follet A., Duru G., and Marquis P. Role of clinical, patient reported outcome and medico-economic studies in the public hospital drug formulary decision-making process: results of a European survey. Health Policy 71 (2005) 205-212
49. Fattore G., and Torbica A. Economic evaluation in health care: the point of view of informed physicians. Value in Health 9 3 (2006) 157-167
50. Williams I.P., and Bryan S. Cost-effectiveness analysis and formulary decision making in England: Findings from research. Social Science & Medicine 65 10 (2007) 2116-2129
51. Buxton M.J. Economic evaluation and decision making in the UK. Pharmacoeconomics 24 11 (2006) 1133-1142
52. Adang E., Voordijk, van der Wilt G.J., and Ament A. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions. Health Policy 74 (2005) 146-156
53. O'Dowd. Government may leave some patients out of 18 week target. BMJ 335 (2007) 1015
54. Neumann P.J. Why don't Americans use cost-effectiveness analysis?. American Journal of Managed Care 10 (2004) 308-312
55. Jonsson B. Economic evaluation of medical technologies in Sweden. Social Science & Medicine 45 (1997) 597-604
56. Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Social Science & Medicine 45 (1997) 563-581
57. Suh D.C., Okpara I.R., Agnese W.B., and Toscani M. Application of pharmacoeconomics to formulary decision making in managed care organizations. American Journal of Managed Care 8 (2002) 161-169
58. Crump B., Drummond M., Alexander S., and Devaney C. Economic evaluation in the United Kingdom health service. In: von der Schulenburg J. (Ed). The influence of economic evaluation studies on health care decision-making (2000), IOS Press and Ohmsha 97-105
59. Miners A., Garau M., Fidan D., and Fischer A. Comparing estimates for cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. British Medical Journal 330 (2005) 65
60. McDaid D., and Cookson R. Evaluating health care interventions in the European Union. Health Policy 63 (2003) 133-139
61. Neumann P.J., and Sullivan S.D. Economic evaluation in the US. What is the missing link?. Pharmacoeconomics 24 11 (2006) 1163-1168
62. Power E.J., and Eisenberg J.M. Are we ready to use cost-effectiveness analysis in health care decision-making? A health services research challenge for clinicians, patients, health care systems, and public policy. Medical Care 36 5 (1998) MS10-MS17
63. Leatherman S., Berwick D., Lles D., Lewin L.S., Davidoff F., Nolan T., et al. The business case for quality: case studies and an analysis. Health Affairs 22 2 (2003) 17-30
64. Martin D.K., Hollenberg D., MacRae S., Madden S., and Singer P. Priority setting in a hospital drug formulary: a qualitative case study and evaluation. Health Policy 66 (2003) 295-303
65. Singer P.A., Martin D.K., Giacominin M., and Purdy L. Priority setting for new technologies in medicine: qualitative case study. British Medical Journal 321 (2000) 1316-1318
66. Martin D.K., Pater J.L., and Singer P.A. Priority setting decisions for new cancer drugs: a qualitative case study. The Lancet 358 (2001) 1676-1681
67. Jenkings K.N., and Barber N. What constitutes evidence in hospital new drug decision making?. Social Science & Medicine 58 (2004) 1757-1766
68. Coast J. Citizens, their agents and health care rationing: an exploratory study using qualitative methods. Health Economics 10 (2001) 159-174
69. Donaldson C., Currie G., and Mitton C. Cost effectiveness analysis in health care: contraindications. British Medical Journal 325 (2002) 891-894
70. Donaldson C., and Mitton C. Economic evaluation and society's health values (rapid response). British Medical Journal (2004)
71. Coast J. Is economic evaluation in touch with society's health values?. British Medical Journal 329 (2004) 1233-1236
72. Mauskopf J.A., Paul J.E., Grant D.M., and Stergachis A. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics 13 (1998) 277-288
73. Mitton C., and Donaldson C. Resource allocation in health care: health economics and beyond. Health Care Analysis 11 (2003) 245-257
74. Peacock S. An evaluation of program budgeting and marginal analysis applied in South Australian hospitals (1998), Centre for Health Program Evaluation
75. Twaddle S., and Walker A. Programme budgeting and marginal analysis: application within programmes to assist purchasing in Greater Glasgow Health Board. Health Policy 33 (1995) 91-105
76. Ruta D., Donaldson C., and Gilray I. Economics, public health and health care purchasing: the Tayside experience of programme budgeting and marginal analysis. Journal of Health Services and Research Policy 1 (1996) 185-193